Moreover, another clinical study of Lestaurtinib in combination with chemotherapy (either Mitozantrone, Etoposide, Cytarabine [MEC], or high-dose Cytarabine [AraC]), combining Lestaurtinib with rigorous chemotherapy appeared possible for young-aged patients with a recently diagnosed FLT3-mutated AML, but actually, no observable clinical outcome was obtained; however, the clinical cases with higher than prolonged sustained 85% FLT3 inhibition percentage had enhanced the existence of those treated patients, proposing that prolonged FLT3 circumvention is vital [67]. Here, FLT3 is linked to acute myeloid leukemia.